IGHE and neoplasm: Although there have been no reports of anaphylaxis in individuals with naturally occurring tumour specific IgE antibodies [6,7], a significant challenge in the development of therapeutic anticancer IgE antibodies has been the consideration of this perceived risk of hypersensitivity.